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Abstract
Background: The aim was to assess time trend of mortality with musculoskeletal disorders (MSD) as underlying
cause of death in Sweden from 1997 to 2013.
Methods: We obtained data on MSD as underlying cause of death across age and sex groups from the National
Board of Health and Welfare's Cause of Death Register. Age-standardized mortality rates per million population for
all MSD, its six major subgroups, and all other ICD-10 (International Classification of Disease) chapters were
calculated. We computed the average annual percent change (AAPC) in the mortality rates across age/sex groups
using joinpoint regression analysis by fitting a regression line to the natural logarithm of the age-standardized
mortality rates and calendar year as a predictor.
Results: There were a total of 7 976 deaths (0.5 % of all causes deaths) with MSD as the underlying cause of
death (32.5 % of these deaths caused by rheumatoid arthritis [RA]). The overall age-standardized mortality rates
(95 % CI) were 16.0 (15.4 to 16.7) and 24.9 (24.1 to 25.7) per million among men and women, respectively
(women/men rate ratio 1.55; 95%CI 1.47 to 1.63). On average, mortality rate declined by 2.3 % per year and only
circulatory system mortality had a more favourable decline than mortality with MSD as underlying cause. Among
MSD the highest decline was observed in RA (3.7 % per year) during study period. Across age groups, while there
were generally stable or declining trends, spondylopathies and osteoporosis mortality among people ≥ 75 years
increased by 2 and 1.5 % per year, respectively.
Conclusion: In overall, mortality with MSD as underlying cause has declined in Sweden over last two decades,
with the highest decline for RA. However, there are variations across MSD subgroups which warrants further
investigations.
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Background
Musculoskeletal disorders (MSD) cover a wide range of
disorders affecting joints, bones, muscles and soft tis-
sues and are considered as the most common cause of
severe long term pain and physical disability [1]. MSD
are highly prevalent worldwide, and in a steadily aging
population with increased prevalence of obesity and re-
duced physical activity, the prevalence of many of MSD
will increase in coming years [2]. Globally, 21.3 % of
years lived with disability was attributed to MSD in
2010 (44.7 % increase from 1990) [3]. MSD were con-
sidered as the fourth (third in developed countries)
greatest contributor in disability-adjusted life years
(DALYs) in 2010 [4].
In spite of substantial burden of MSD on individuals
and societies, there is a lack of adequate recognition at
the level of policy-making or priority [5]. In response to
this, the Bone and Joint Decade 2000–2010 was en-
dorsed by the United Nations and the World Health
Organization [6]. While less attention had been paid to
mortality associated with MSD, a growing recognition of
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MSD-related mortality has been emerged in recent years
[7–9]. Recent evidence suggests that MSD including
rheumatoid arthritis (RA) and osteoarthritis (OA) are as-
sociated with excess all-cause and disease-specific mor-
tality [10–15]. In the Global Burden of Disease Study,
MSD were considered as underlying cause of 153 500
deaths worldwide in 2010 (about 0.3 % of all causes
deaths) and age-standardized mortality rate increased
from 17 per million in 1990 to 23 per million in 2010 (a
37.8 % increase) [16]. It should be noted that these num-
bers are underestimated because MDS are likely under-
reported on death certificates especially as underlying
cause of death [5, 17].
Although, the accuracy of death certificates has been
questioned [17–19], these are the main source of mortal-
ity data available for whole populations at often national
level, and they are widely used in cause of death ana-
lyses. While a few studies have investigated time trend
of a specific MSD such as RA [8, 20, 21] and systemic
lupus erythematosus [22–24], updated information on
mortality is needed, for instance due to the introduction
of new biological drugs in the treatments of many in-
flammatory rheumatic diseases. Also, to our best know-
ledge, no previous study has investigated all mortality
associated with MSD and its major subgroups in a single
study using the same data source and uniform method-
ology. Thus, our aim was to provide an up-to-date data
on the recent trend of mortality with MSD and its six
subgroups as underlying cause in Sweden during 1997–
2013. Such data not only provide tools to monitor pro-
gress towards national public health goals but also helps
to evaluate interventions, to identify high risk population
subgroups, and to make future projections.
Methods
Data sources
Data on population across sex and age groups were col-
lected from the Statistics Sweden (http://www.scb.se).
Data on mortality were obtained from the National
Board of Health and Welfare's Cause of Death Register
which includes all those who died during one calendar
year and were registered in Sweden at the time of
death, regardless of whether the death occurred inside
or outside the country. The causes of death are coded
centrally at the Statistics Sweden according to the
International Classification of Diseases, the 10th revi-
sion (ICD-10). The Cause of Death Register contains a
single underlying cause of death, up to 48 additional
contributory causes of death, and demographic data.
For this study we used publicly available data which
includes only the underlying cause of death by sex, age,
region, and year (http://www.socialstyrelsen.se/statis-
tics/statisticaldatabase/causeofdeath). MSD were identi-
fied as ICD-10 codes M00-M99. In addition, six major
subcategories of MSD with higher mortality rates were
identified: pyogenic arthritis (M00), RA (M05-M06),
OA (M15-M19), systemic connective tissue disorders
(M30-M35), spondylopathies (M45-M48), and osteopor-
osis (M80-M81). To compare the trend in mortality with
MSD as underlying cause with trend in mortality from
other diseases over the study period, we also included fif-
teen other ICD-10 chapters (Table 3 in Appendix). Due to
very low mortality over study period, the following
ICD-10 chapters were excluded: Diseases of the eye and
adnexa (H00-H59); Diseases of the ear and mastoid
process (H60-H95); and Pregnancy, childbirth and the
puerperium (O00-O99).
Statistical analysis
Age-standardized mortality rates per 1 million popula-
tion were calculated by means of direct standardization
using the WHO Reference Population [25]. These age-
standardized rates were calculated across age and sex
groups. We also computed women to men age-
standardized rate ratio and its 95 % confidence interval
[26]. The percent change was calculated as the difference
between the average age-standardized rate of the last
two years and the average rate of the first two years di-
vided by the average rate the first two years. Time trends
in age-standardized mortality rate were analyzed using
joinpoint regression. This was done using the Joinpoint
Regression Program version 4.2.0.2 from the Surveillance
Research Program of the US National Cancer Institute
(http://surveillance.cancer.gov/joinpoint). Joinpoint re-
gression identifies points with a significant change in
trend (“joinpoints”) and determined linear trends be-
tween joinpoints. In the software a series of permuta-
tion tests proposed by Kim et al. [27] is applied to
compute the number of joinpoints to best fit the data.
For each joinpoint an annual percentage change (APC)
is estimated by fitting a regression line to the natural
logarithm of the age-standardized rates, using calendar
year as a predictor. The average annual percent change
(AAPC) as the weighted average of APCs was com-
puted to provide a summary measure of the trend for
the whole time period [28]. We used the empirical
quantile method with 1 000 resamples to calculate 95 %
confidence interval of AAPC. Since the empirical quan-
tile method is not available for comparison between
groups, we used parametric method to compare AAPC
of MSD mortality with other ICD-10 chapters. In trend
analysis across age groups, due to low number of death
in MSD subcategories, we smoothed the mortality rates
using a four-year moving average.
It has been suggested that several MSD should not be
considered as underlying cause of death (defined as “gar-
bage codes”, Table 4 in Appendix) [29]. In a sensitivity
analysis, we calculated the AAPC excluding deaths
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attributed to these causes. It should be noted that across
the MSD subcategories, excluding these “garbage codes”
only influenced OA and spondylopathies. In addition,
because all OA codes (M15-M19) are considered as
“garbage codes”, we did our sensitivity analysis only on
all MSD and spondylopathies.
Results
During 1997 to 2013, 2 411 men and 5 565 women had
a MSD registered as their underlying cause of death in
Sweden (0.3 and 0.7 % of all causes mortality among
men and women, Table 5 in Appendix). In overall,
among MSD, RA was the leading cause of death (32.5 %
all deaths) followed by systemic connective tissue disor-
ders (23.4 % of all deaths). Across age and sex groups,
while RA was the leading cause of death for men and
women aged 65 years and older, among younger people
systemic connective tissue disorders were associated
with the highest number of deaths (45.9 % of all death in
this age group, Fig. 1).
The overall age-standardized mortality rates (95 %
CI) were 16.0 (15.4 to 16.7) and 24.9 (24.1 to 25.7) per
million among men and women, respectively. This fig-
ures corresponded to a statistically significant women/
men rate ratio (95 % CI) of 1.55 (1.47 to 1.63). Across
MSD subcategories, while women had statistically sig-
nificantly a higher age-standardized mortality rate for
RA, systemic connective tissue disorders, and osteopor-
osis as underlying cause compared to men, opposite
was observed for pyogenic arthritis and spondylopa-
thies (Table 1).
The age-standardized mortality rate of MSD as under-
lying cause for Swedish population declined from 24.7
per million in 1997 to 17.2 per million in 2013 (a per-
cent change of −27.8 %, Fig. 2a). While women had
higher mortality rates than men in all study years, the
disparity was declining over time. Across age groups,
while age-standardized rate substantially declined in
2013 compared to 1997 among younger age groups (the
percent change of −42.2 and −45.0 % in 0–64 and 65–74
years groups, respectively), a smaller decline of 9.7 %
was observed among oldest age group (from 365.3 per
million in 1997 to 342.3 per million in 2013, Fig. 2b).
On average, the age-standardized mortality rate de-
clined by 2.3 % (95 % CI: 1.5 to 3.1) annually during the
study period in Sweden (Fig. 3). Among MSD subcat-
egories while there were statistically significant declining
trend for RA, OA, systemic connective tissue disorders,
and spondylopathies, the trends for pyogenic arthritis
and osteoporosis were stable during 1997–2013. Among
ICD-10 chapters, only diseases of the circulatory system
(I00-I99) had a more profound reduction than MSD
(Table 2). There was no statistically significant difference
in AAPC of MSD and four other chapters (i.e., diseases
of the respiratory system (J00-J99), diseases of the geni-
tourinary system (N00-N99), certain conditions originat-
ing in the perinatal period (P00-P96), and congenital
malformations, deformations and chromosomal abnor-
malities (Q00-Q99)).
Fig. 1 Percentage of death due to musculoskeletal disorders by sex, age and cause in Sweden, 1997–2013
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Our subgroup analyses across age and sex groups re-
vealed that among men and women the highest decline
was observed in RA (3.2 % per year) and OA (4.9 % per
year), respectively. While women experienced a statisti-
cally significant decline in mortality with systemic con-
nective tissue disorders as underlying cause, this was
relatively constant among men (AAPC = −2.0 %, P =
0.20). Across age groups, the oldest age group (75+
years) experienced less profound changes in mortality
with MSD as underlying cause (Fig. 4). While people
aged 0–64 experienced a statistically significant decline
in mortality with pyogenic arthritis as underlying cause,
the trend was constant among older people. On the
other hand, the trend in mortality with OA as under-
lying cause was constant among people aged 0–64 years
and declining among older age groups. In addition,
while mortality with spondylopathies and osteoporosis
as underlying cause were either declining or constant
among younger age groups (i.e., 0–64, and 65–74
years), these have increased among the oldest age group
during the study period. Of course, mortality rate of
osteoporosis as underlying cause steadily declined by
1.2 % per year since 2001 but a sharp increase of 10.9 %
per year during 1997–2001 resulted in an overall in-
creasing trend for this subgroup.
A total of 1 543 (19.3 %) of deaths with MSD as
underlying cause were attributed to garbage codes (25.7
and 16.6 % of deaths among men and women, respect-
ively, Table 5 in Appendix). Excluding these potential
garbage codes had negligible impact on AAPC of mor-
tality with MSD as underlying cause among women and
in total population (among women AAPC changed from
Table 1 Overall age-standardized mortality rate of musculoskeletal disorders as underlying cause per million people in Sweden,
1997–2013
ICD title (codes) Women Men Women/men rate ratio
All musculoskeletal disorders (M00-M99) 24.9 (24.1 to 25.7) 16.0 (15.4 to 16.7) 1.6 (1.5 to 1.6)
Pyogenic arthritis (M00) 0.56 (0.46 to 0.67) 0.94 (0.79 to 1.09) 0.60 (0.47 to 0.76)
Rheumatoid arthritis (M05-M06) 8.9 (8.5 to 9.4) 3.4 (3.2 to 3.7) 2.6 (2.4 to 2.9)
Osteoarthritis (M15-M19) 0.94 (0.80 to 1.1) 1.0 (0.88 to 1.2) 0.90 (0.73 to 1.1)
Systemic connective tissue disorders (M30-M35) 7.3 (6.8 to 7.7) 4.2 (3.9 to 4.6) 1.7 (1.6 to 1.9)
Spondylopathies (M45-M48) 0.75 (0.64 to 0.87) 1.4 (1.2 to 1.6) 0.55 (0.45 to 0.67)
Osteoporosis (M80-M81) 2.1 (1.9 to 2.2) 0.45 (0.35 to 0.54) 4.7 (3.7 to 5.9)
Fig. 2 Age-standardized mortality rate (95 % CI) of musculoskeletal disorders as underlying cause across sex and age groups in Sweden, 1997–2013
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−2.2 to −2.7 % and in total population from −2.3 to
−2.1 %). However, excluding these garbage codes re-
sulted in a statistically non-significant AAPC of −0.9 %
(P = 0.21) among men. In addition, across age groups,
the declining trend for mortality with MSD as under-
lying cause among people aged ≥ 75 years was no longer
statistically significant (AAPC = −0.5 %, P = 0.45). For
mortality with spondylopathies as underlying cause, the
exclusion of garbage codes only influenced the trend for
the total population and it became no longer statistically
significant (AAPC = −0.3 %, P = 0.88).
Discussion
In the current study, we have presented an up-to-date
data on recent trends in mortality with MSD and its six
major subcategories as underlying cause in Sweden. Our
results showed that MSD were recorded as underlying
cause of death on 0.5 % of all death certificates during
1997–2013. We found evidence that mortality with
MSD as underlying cause declined during the study
period and its annual decline was generally more pro-
found than for other disease categories. Although the
age-standardized mortality rates of MSD as underlying
cause declined in both men and women, our subgroup
analyses revealed important variations in MSD subcat-
egories across age and sex groups. In addition, while
women had higher mortality rates compared with men,
this gender disparity was declining over time.
Comparing the recent (2007–2013) mortality with
MSD as underlying cause in Sweden with Denmark
(http://www.statbank.dk/), Australia (http://www.aihw.go-
v.au/deaths/grim-books/) and USA (http://wonder.cdc.-
gov/ucd-icd10.html) showed that while the proportion of
MSD from all-cause mortality was similar across coun-
tries (0.5 % in Sweden, 0.6 % in USA, and 0.8 % in
Denmark and Australia), Sweden had the lowest age-
Fig. 3 Average annual percent change of mortality with musculoskeletal disorders as underlying cause in Sweden obtained from joinpoint
regression analysis 1997–2013
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standardized mortality rate (pooled age-standardized
mortality rate per million people: Sweden 21.1, USA
26.3, Denmark 32.9, and Australia 26.4). The differ-
ences in sociodemographic status, health care system,
and mortality coding practices might be potential rea-
sons for observed difference in mortality rates across
these countries.
We found that mortality with MSD its four subcategor-
ies (i.e. RA, OA, systemic connective tissue disorders, and
spondylopathies) as underlying cause statistically signifi-
cantly declined in Sweden over the study period. This
finding is in line with declining trend in mortality from
RA, systemic lupus erythematosus, ankylosing spondylitis
and polyarteritis nodosa in France [8], Spain [24], and
England [30]. Better management of MSD induced by
advancement in pharmacological interventions and
medical procedures might explain this observed declin-
ing trend. For example, a recent study showed that time
Table 2 Annual percent change and average annual percent change in age-standardized mortality rates for ICD-10 chapters, 1997–2013
ICD-10 chapter (codes) Age-standardized mortality
rate per million people
Period APC, % AAPC, % Mean difference (95 % CI)
in AAPC compared with
MSD (M00-M99)
1997 2013
Certain infectious and parasitic diseases (A00-B99) 45.2 85.3 1997–2013 4.25*** 4.25*** 6.54 (5.71 to 7.37)
Neoplasms (C00-D48) 1270.7 1084.9 1997–2005 −0.57*** −0.92*** 1.34 (0.72 to 2.03)
2005–2010 −1.73***
2010–2013 −0.49
Diseases of the blood and blood-forming organs
and certain disorders involving the immune
mechanism (D50-D89)
10.0 11.3 1997–2013 0.61 0.61 2.90 (1.88 to 3.91)
Endocrine, nutritional and metabolic diseases (E00-E90) 104.4 102.6 1997–2005 0.97 −0.15 2.15 (1.22 to 3.07)
2005–2013 −1.24*
Mental and behavioural disorders (F00-F99) 141.7 184.4 1997–1999 11.54 1.67 3.97 (1.87 to 6.06)
1999–2010 −0.61
2010–2013 3.89
Diseases of the nervous system (G00-G99) 99.9 159.6 1997–2013 3.39*** 3.39*** 5.69 (4.93 to 6.44)
Diseases of the circulatory system (I00-I99) 2038.4 1202.0 1997–2002 −2.83*** −3.27*** −0.98 (−1.76 to −0.20)
2002–2005 −4.55**
2005–2013 −3.07***
Diseases of the respiratory system (J00-J99) 303.4 227.9 1997–2010 −2.71*** −1.65** 0.64 (−0.69 to 1.98)
2010–2013 3.06
Diseases of the digestive system (K00-K93) 141.7 120.3 1997–2006 −0.01 −1.30** 0.99 (0.01 to 1.98)
2006–2013 −2.92**
Diseases of the skin and subcutaneous tissue (L00-L99) 7.0 6.3 1997–2013 −0.53 −0.53 1.76 (0.58 to 2.94)
Diseases of the musculoskeletal system and connective
tissue (M00-M99)
24.7 17.2 1997–2013 −2.29*** −2.29*** -
Diseases of the genitourinary system (N00-N99) 54.2 38.5 1997–2013 −2.80*** −2.80*** −0.51 (−1.37 to 0.36)
Certain conditions originating in the perinatal
period (P00-P96)
23.1 21.9 1997–2003 5.40* −0.58 1.71 (−3.28 to 6.70)
2003–2006 −14.93
2006–2013 1.09
Congenital malformations, deformations and
chromosomal abnormalities (Q00-Q99)
36.5 25.4 1997–2013 −3.14*** −3.14*** −0.85 (−1.82 to 0.13)
Symptoms, signs and abnormal clinical and
laboratory findings, not elsewhere classified (R00-R99)
95.7 123.2 1997–2007 1.09 0.85 3.14 (0.05 to 6.23)
2007–2010 13.79
2010–2013 −11.30**
External causes of morbidity and mortality (V01-Y98) 338.6 309.3 1997-2013 −0.78* −0.78* 1.51 (0.71 to 2.31)
*** P< 0.001; ** P< 0.01; * P< 0.05
APC annual percent change, AAPC average annual percent change, MSD musculoskeletal disorders
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to initiation disease modifying antirheumatic drug has
substantially shortened over the past four decades
among people with RA [31]. Nevertheless, analysis
across age groups revealed an increase in mortality with
spondylopathies and osteoporosis as underlying cause
among the oldest (aged ≥ 75 years). This might be due
to aging population which has increased number of
older people. Moreover, promoted awareness of the sever-
ity of these conditions in recent years might have in-
creased reporting them as a cause of death [32]. Further
research is required to explain these increasing trends
among the most elderly.
The mortality rates of MSD and its three subcategories
(i.e., RA, systemic connective tissue disorders, and osteo-
porosis) as underlying cause were higher among women
compared to men and this is mainly attributed to higher
prevalence of these disorders among women [33, 34].
Previous studies have suggested similar gender inequality
for RA [8, 20, 21], dermatomyositis and polymyositis
[35], and systemic lupus erythematosus [22, 24]. On the
other hand, men had higher mortality rates of pyogenic
arthritis and spondylopathies as underlying cause com-
pared with women. The similar pattern for ankylosing
spondylitis was observed in England [30]. This might
be due to higher prevalence of these disorders among
men and also difference in severity of disease. For ex-
ample, previous studies reported a higher prevalence of
ankylosing spondylitis, lumbar spondylosis, and cervical
spondylosis among men [36–38] and a tendency to
have more severe ankylosing spondylitis compared with
women [39]. While, these gender gaps were generally
closing over time, more efforts are required for further
reduction. For example, if we naively assume that the
projected trends in mortality with MSD as underlying
Fig. 4 Average annual percent change of mortality with musculoskeletal disorders as underlying cause in Sweden obtained from joinpoint
regression analysis, by age groups 1997–2013. Footnote: The mortality rates for subgroups of musculoskeletal disorders are four-year moving
average rates
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cause will be observed during next 10 years, then
AAPC for women should be doubled during this period
(i.e., increase from −2.2 to −4.7 %) in order to close ob-
served gender gap in our study.
The limitations of the current study should also be
considered when interpreting its findings. We only ana-
lyzed mortality due to underlying cause of death which
suffers from underestimation for MSD as these are not
usually considered as underlying cause of death [5]. In-
accuracy and errors in completion of death certificate
are another potential limitation of our study, but is un-
likely to have substantially changed over time [18]. The
small number of deaths, especially for MSD subgroups,
might have limited the power of our study to detect sig-
nificant joinpoints during the study period. In addition,
because our study was an ecological study with no
individual-level data available, we were unable to adjust
for any potential confounders in addition to age and
sex. Also, we cannot further examine factors influen-
cing the observed trend in mortality with MSD as
underlying cause. In spite of these limitations, the
current study have important implications including
new insight about recent temporal trends in mortality
with MSD as underlying cause of death which might be
used to predict mortality rates in coming years in
Sweden. The findings can be used to develop a hypoth-
esis that increased use of biological treatments in e.g.
RA has impacted on mortality associated with MSD. In
addition, the observed increasing trends in mortality
with spondylopathies and osteoporosis as underlying
cause require further attention.
Conclusion
The mean age-standardized mortality rate with MSD as
underlying cause was 21.1 per million people per year
in Sweden during 1997–2013. The present study indi-
cated that mortality with MSD as underlying cause de-
clined by 2.3 % per year in Sweden and this reduction
was generally more favourable than other ICD-10 chap-
ters. However, we found variations in time trends for
MSD subcategories across sex and age groups. Our
findings revealed that older people (aged ≥ 75 years) ob-
served an increasing trend in mortality with spondylo-
pathies and osteoporosis as underlying cause which
warrants further investigations. Moreover, while mor-
tality rates of MSD and its three subcategories (RA,
systemic connective tissue disorders, and osteoporosis)
as underlying cause were higher among women, more
Swedish men died from pyogenic arthritis and spondy-
lopathies during the study period. Analyzing time trend
in MSD mortality using multiple cause of death frame-
work and using individual-level data are subjects for fu-
ture studies.
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Table 3 The ICD-10 chapters included in the study for comparison
ICD-10 title ICD codes
Certain infectious and parasitic diseases A00-B99
Neoplasms C00-D48
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism D50-D89
Endocrine, nutritional and metabolic diseases E00-E90
Mental and behavioural disorders F00-F99
Diseases of the nervous system G00-G99
Diseases of the circulatory system I00-I99
Diseases of the respiratory system J00-J99
Diseases of the digestive system K00-K93
Diseases of the skin and subcutaneous tissue L00-L99
Diseases of the genitourinary system N00-N99
Certain conditions originating in the perinatal period P00-P96
Congenital malformations, deformations and chromosomal abnormalities Q00-Q99
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified R00-R99
External causes of morbidity and mortality V01-Y98
Appendix
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Table 4 Musculoskeletal disorders considered as garbage codes and excluded in a sensitivity analysis
ICD-10 title ICD codes Total number of deaths 1997-2013
Men Women
Postinfective and reactive arthropathies in diseases classified elsewhere M03 0 0
Psoriatic and enteropathic arthropathies M07 0 0
Juvenile arthritis in diseases classified elsewhere M09 0 0
Gout M10 19 28
Other crystal arthropathies M11 2 3
Other specific arthropathies M12 0 0
Arthropathies in other diseases classified elsewhere M14 0 0
Osteoarthritis M15-M19 165 227
Other joint disorders M20-M25 93 145
Kyphosis and lordosis M40 14 52
Spondylosis M47 9 5
Other spondylopathies M48 81 154
Spondylopathies in diseases classified elsewhere M49 0 0
Cervical disc disorders M50 5 6
Other intervertebral disc disorders M51 10 6
Other dorsopathies, not elsewhere classified M53 4 5
Dorsalgia M54 15 23
Myositis M60 45 27
Disorders of muscle in diseases classified elsewhere M63 0 0
Disorders of synovium and tendon M65-M68 1 4
Soft tissue disorders related to use, overuse and pressure M70 11 7
Other bursopathies M71 9 2
Soft tissue disorders in diseases classified elsewhere M73 0 0
Shoulder lesions M75 0 0
Enthesopathies of lower limb, excluding foot M76 0 0
Other enthesopathies M77 0 0
Other soft tissue disorders, not elsewhere classified M79 27 105
Osteomyelitis M86 104 112
Other disorders of the musculoskeletal system and connective tissue M95-M99 5 13
Table 5 Number of death across musculoskeletal disorders subgroups by sex and year
ICD-10 title (codes) 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Infectious arthropathies
(M00-M03)
Men 13 6 9 4 6 10 11 4 13 5 10 5 9 15 11 13 15
Women 9 6 15 15 7 6 5 8 8 9 3 12 7 11 13 6 7
Inflammatory polyarthropathies
(M05-M14)
Men 41 35 37 27 41 37 44 37 33 34 41 26 26 24 37 32 36
Women 127 137 159 151 161 118 133 108 128 131 126 125 134 107 110 113 90
Osteoarthritis (M15-M19) Men 6 12 13 13 8 11 10 11 9 12 8 6 10 10 9 8 9
Women 18 16 16 13 13 13 8 12 13 14 13 14 15 8 16 13 12
Other joint disorders
(M20-M25)
Men 14 18 13 9 3 2 0 4 2 3 0 2 3 6 4 5 5
Women 15 29 30 11 8 5 4 4 6 2 5 2 1 6 4 5 8
Systemic connective tissue
disorders (M30-M36)
Men 34 40 43 31 29 42 38 28 33 28 37 43 30 41 45 24 30
Women 79 81 91 90 82 73 73 79 74 65 72 79 71 65 63 70 65
M40-M43 Deforming
dorsopathies (M40-M43)
Men 2 2 3 4 2 4 4 8 5 8 10 1 6 5 2 7 5
Women 5 11 9 10 11 17 13 10 6 13 14 16 13 17 13 9 10
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